Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A011
- Development stage
- Preclinical
- Lead developer
- Sichuan University
01
Overview
A011: sourced facts only. name: "Among the inhibitors, A011 was one of the most potent, with an IC50 value of 1.0 nM against ATM." [PMID:37312863]; target: "Among the inhibitors, A011 was one of the most potent, with an IC50 value of 1.0 nM against ATM." [PMID:37312863]; developer: "Key Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan 610041, PR China." [PMID:37312863]; stage: "In the SW620 human colorectal adenocarcinoma tumor xenograft model, A011 sensitized SW620 to CPT-11 by inhibiting ATM activity." [PMID:37312863]
02
Targets
ATM (Ataxia telangiectasia mutated protein)
Beyond the preview
Go deeper on A011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on A011.